The global mergers and acquisitions (M&A) market has roared back to life in the first quarter of 2026, shattering expectations and signaling a definitive end to the dealmaking drought of previous years. As of late March, total announced deal volume has surged past the $1 trillion milestone, a 27%
As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic $813.3 billion, a massive 50% increase over the same period last year. This record-breaking figure
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from its consolidation ambitions. Instead, strategic buyers have evolved, trading the broad "mega-merger" attempts of the past for targeted,
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
As of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise. Driven by a historic surge in private equity confidence—now sitting at a six-year high of 86%—the deal-making
The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a decade. Driven by a historic flood of "dry powder" and a rapidly stabilizing macroeconomic environment,
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
What a brutal six months it’s been for Boston Scientific. The stock has dropped 29% and now trades at $76.39, rattling many shareholders. This might have inv...
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
In a dramatic departure from his historically cautious stance, Mike Wilson, Chief U.S. Equity Strategist at Morgan Stanley (NYSE: MS), has stunned Wall Street by raising the firm’s 12-month S&P 500 price target to a lofty 7,800. This projection, released as the market moves through the
